Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma

Annals of Allergy, Asthma and Immunology

Volumn 109, Issue 1, 2012, Pages 59-64

  Lafeuille, Marie Hélène ^a   Dean, Jason ^a   Zhang, Jie ^b   Duh, Mei Sheng ^c   Gorsh, Boris ^b   Lefebvre, Patrick ^a  

^a GROUPE D ANALYSE   (Canada)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ANALYSIS GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; OMALIZUMAB;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; DRUG MEGADOSE; DRUG USE; EMERGENCY WARD; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME; UNCONTROLLED ASTHMA;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; EMERGENCY SERVICE, HOSPITAL; FEMALE; HOSPITALIZATION; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84862902367     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/j.anai.2012.04.015     Document Type: Article

References (25)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention 2010 (update). Available at: http://www.ginasthma.org/ pdf/GINA-Report-2010.pdf. Accessed October 28, 2011.
2. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. NIH Publication: 08-5846. Bethesda, MD: National Institutes of Health, 2007.
3. Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. National Cancer for Health Statistics. Vital Health Stat. 2010;10:249.
4. Bloom B, Cohen RA, Freeman G. F. Summary health statistics for U.S. children: National Health Interview Survey, 2009. National Cancer for Health Statistics. Vital Health Stat. 2010;10:247.
5. Akinbami LJ, Moorman JE, Liu X. Asthma prevalence, health care use, and mortality: United States, 2005-2009. National Health Statistics Reports; no 32. Hyattsville, MD: National Center for Health Statistics, 2011.
6. Mullane K. The increasing challenge of discovering asthma drugs. Biochem Pharmacol. 2011;82:586-599.
7. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836-844. (Pubitemid 39346477)
8. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet. 2001;357:2007-2011. (Pubitemid 32592387)
9. Nathan RA, Yancey SW, Waitkus-Edwards K, et al. Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall asthma control. Chest. 2005;128:1910-1920. (Pubitemid 41507521)
10. The American Lung Association Asthma Clinical Research Centers. Clinical trial of low-dose theophylline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med. 2007;175:235-242.
11. Walsh LJ, Wong CA, Oborne J, et al. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax. 2001;56:279-284. (Pubitemid 32269807)
12. Xolair® (omalizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc. and Novartis Pharmaceuticals Corporation, East Hanover 2010. Available at: http://www.gene.com/gene/products/information/pdf/ xolairprescribing.pdf. Accessed October 28, 2011.
13. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184-190. (Pubitemid 32735398)
14. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254-261. (Pubitemid 32776398)
15. Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy. 2004;34:632-638. (Pubitemid 38534897)
16. Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004;59:709-717. (Pubitemid 38850345)
17. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005;60:309-316. (Pubitemid 40293346)
18. Niven R, Chung KF, Panahloo Z, Blogg M, Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respiratory Medicine. 2008;102:1371-1378.
19. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573-582.
20. Zeiger RS, Schatz M, Li Q, et al. Step-up care improves impairment in uncontrolled asthma: an administrative data study. AJMC. 2010;16:897-906.
21. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;11:1130-1139. (Pubitemid 41587600)
22. Molimard M, Buhl R, Niven R, et al. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med. 2010;104:1381-1385.
23. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med. 2009;103:975-994.
24. Faries DE, Nyhuis AW, Ascher-Svanum H. Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example. Cost Eff Resour Alloc. 2009;7:11.
25. Gianfrancesco F, Wang RH, Mahmoud R, White R. Methods for claims-based pharmacoeconomic studies in psychosis. Pharmacoeconomics. 2002;20:499-511. (Pubitemid 34848336)